A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Mise à jour : Il y a 4 ans
Référence : NCT01150448

Femme et Homme

Extrait

The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to document the pharmacokinetics of paliperidone following fixed multiple intramuscular injections of paliperidone palmitate 150 mg eq.


Critère d'inclusion

  • Schizophrenia


Liens